MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.medj.2024.02.003

Медицинская библиотека · Med (New York, N.Y.) · 2024

Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.

Knisely Anne, Hinchcliff Emily, Fellman Bryan, Mosley Ann, Lito Kathryn, Hull Sara, Westin Shannon N, Sood Anil K, Schmeler Kathleen M, Taylor Jolyn S, Huang Steven Y, Sheth Rahul A, Lu Karen H, Jazaeri Amir A

Клиническое исследование I фазыСтатьяПоддержка исследования: вне правительства СШАResearch Support, N.I.H., IntramuralПеревод пока не подготовлен

Аннотация

BACKGROUND

Intravenous immune checkpoint blockade (ICB) has shown poor response rates in recurrent gynecologic malignancies. Intraperitoneal (i.p.) ICB may result in enhanced T cell activation and anti-tumor immunity.

METHODS

In this phase 1b study, registered at Clinical.

TRIALS: gov (NCT03508570), initial cohorts received i.p. nivolumab monotherapy, and subsequent cohorts received combination i.p. nivolumab every 2 weeks and i.p. ipilimumab every 6 weeks, guided by a Bayesian design. The primary objective was determination of the recommended phase 2 dose (RP2D) of the combination. Secondary outcomes included toxicity, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

FINDINGS: The trial enrolled 23 patients: 18 with ovarian cancer, 2 with uterine cancer, and 3 with cervical cancer. Study evaluable patients (n = 16) received a median of 2 prior lines of therapy (range: 1-8). Partial response was observed in 2 patients (12.5%; 1 ovarian, 1 uterine), and complete response was observed in 1 patient (6.3%) with cervical cancer, for an ORR of 18.8% (95% confidence interval: 4.0%-45.6%). The median duration of response was 14.8 months (range: 4.1-20.8), with one complete response ongoing. Median PFS and OS were 2.7 months and not reached, respectively. Grade 3 or higher immune-related adverse events occurred in 2 (8.7%) patients.

CONCLUSIONS

i.p. administration of dual ICB is safe and demonstrated durable responses in a subset of patients with advanced gynecologic malignancy. The RP2D is 3 mg/kg i.p. nivolumab every 2 weeks plus 1 mg/kg ipilimumab every 6 weeks.

FUNDING: This work was funded by Bristol Myers Squibb (CA209-9C7), an MD Anderson Cancer Center Support Grant (CA016672), the Ovarian Cancer Moon Shots Program, the Emerson Collective Fund, and a T32 training grant (CA101642).

Для цитирования: Knisely Anne, Hinchcliff Emily, Fellman Bryan, Mosley Ann, Lito Kathryn, Hull Sara, Westin Shannon N, Sood Anil K, Schmeler Kathleen M, Taylor Jolyn S, Huang Steven Y, Sheth Rahul A, Lu Karen H, Jazaeri Amir A. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.. Med (New York, N.Y.). 2024. DOI: 10.1016/j.medj.2024.02.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.